FDA approves first epoetin alfa biosimilar for the treatment of anemia - FDA.gov

Endpoints News

FDA approves first epoetin alfa biosimilar for the treatment of anemia FDA.gov May 15, 2018. Release. The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine ... FDA approves Retacrit, an Epogen/Procrit biosimilar, for treatment of anemiaHealio 'BioSimilar' Drug Approved to Treat Certain Types of AnemiaHealthDay all 12 news articles »

from Health - Google News https://ift.tt/2jZosSM